Positions

Selected Publications

Academic Article

Year Title Altmetric
2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016

Chapter

Year Title Altmetric
2019 Sources of cells for hematopoietic cell transplantation.  73-84. 2019

Investigator On

  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS
  • Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen  awarded by University of Michigan
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC.
  • Private Grant  awarded by ASTELLAS PHARMA US, INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARRAY BIOPHARMA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC.
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by MUNDIPHARMA
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC.
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program
  • The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma  awarded by National Cancer Institute/NIH/DHHS
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center
  • Education And Training

  • Atlanta Medical Center, Internship
  • Atlanta Medical Center, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • University of Virginia Hospital, Postdoctoral Fellowship
  • Doctor of Medicine in Internal Medicine Residency Program, Medical College of Georgia 1998
  • Full Name

  • Racquel Innis-Shelton